Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Research analysts at Leede Financial reduced their FY2027 earnings per share estimates for Cardiol Therapeutics in a report released on Tuesday, November 19th. Leede Financial analyst D. Loe now anticipates that the company will post earnings of $0.16 per share for the year, down from their prior forecast of $0.18. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.36) per share. Leede Financial also issued estimates for Cardiol Therapeutics' FY2028 earnings at $0.74 EPS.
Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a report on Wednesday. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $8.75.
Get Our Latest Stock Report on CRDL
Cardiol Therapeutics Trading Down 5.8 %
Shares of CRDL traded down $0.10 during trading on Wednesday, reaching $1.56. 561,650 shares of the company traded hands, compared to its average volume of 419,561. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The stock has a market cap of $126.89 million, a PE ratio of -4.23 and a beta of 0.91. The stock has a 50-day simple moving average of $1.98 and a 200-day simple moving average of $2.09. Cardiol Therapeutics has a twelve month low of $0.79 and a twelve month high of $3.12.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in Cardiol Therapeutics during the 3rd quarter valued at $29,000. Townsquare Capital LLC acquired a new stake in Cardiol Therapeutics during the 3rd quarter worth about $27,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Cardiol Therapeutics in the 3rd quarter valued at approximately $27,000. Foundations Investment Advisors LLC grew its stake in Cardiol Therapeutics by 237.4% during the 3rd quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company's stock valued at $321,000 after acquiring an additional 113,950 shares in the last quarter. Finally, Lion Street Advisors LLC increased its stake in shares of Cardiol Therapeutics by 7.9% in the third quarter. Lion Street Advisors LLC now owns 273,281 shares of the company's stock worth $544,000 after acquiring an additional 20,000 shares during the last quarter. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Recommended Stories
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
